Analytical Data
-
Gene name
MAGEA1
- Application
-
Alternative Names
MAGEA1；MAGE1；MAGE1A；Melanoma-associated antigen 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43355
-
Expression Region
1-309aa
-
AA Sequence
MSLEQRSLHCKPEEALEAQQEALGLVCVQAATSSSSPLVLGTLEEVPTAGSTDPPQSPQGASAFPTTINFTRQRQPSEGSSSREEEGPSTSCILESLFRAVITKKVADLVGFLLLKYRAREPVTKAEMLESVIKNYKHCFPEIFGKASESLQLVFGIDVKEADPTGHSYVLVTCLGLSYDGLLGDNQIMPKTGFLIIVLVMIAMEGGHAPEEEIWEELSVMEVYDGREHSAYGEPRKLLTQDLVQEKYLEYRQVPDSDPARYEFLWGPRALAETSYVKVLEYVIKVSARVRFFFPSLREAALREEEEGV
-
Molecular Weight
36.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA1 (Melanoma Antigen Gene A1) is a member of the cancer/testis (CT) antigen family, which is predominantly expressed in germ cells and various tumors but is normally silent in adult somatic tissues. This unique expression pattern makes MAGEA1 an appealing target for cancer immunotherapy. Research has shown that MAGEA1 is involved in several malignancies, including melanoma and other solid tumors, offering potential avenues for diagnostic and therapeutic applications. Recombinant MAGEA1 protein has been produced for the purpose of understanding its function and role in tumor immunity. Studies have focused on its ability to elicit T-cell responses in cancer patients, paving the way for its development as a vaccine component. By exploring the immunogenic properties of the MAGEA1 antigen, researchers hope to enhance the efficacy of cancer immunotherapies, including personalized vaccines and adoptive T-cell transfer. Furthermore, elucidating the mechanisms underlying MAGEA1's role in tumor biology may provide insights into novel therapeutic strategies and biomarkers for cancer prognosis. As research progresses, the therapeutic potential of MAGEA1 continues to be of significant interest in oncology, highlighting the importance of investigating its recombinant protein to better understand its implications in cancer treatment.
